Inhibitors of APOL1 and methods of using same

US11618746B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Jingrong Cao · Newton, US
• Jon Come · Cambridge, US
• Leslie Dakin · Waltham, US
• Francois Denis · Saint Lazare, CA
• Warren Dorsch · Boston, US
• Anne Fortier · Rockville, US
• Martine Hamel · Boston, US
• Elaine B. Krueger · Cambridge, US
• Brian Ledford · Attleboro, US
• Suganthini S. Nanthakumar · Newton, US
• Olivier Nicolas · Winston-Salem, US
• Camil SAYEGH · Belmont, US
• Timothy J. Senter · Arlington, US
• Tiansheng Wang · Concord, US
• Michael Aaron Brodney · East Lyme, US
• Kan-Nian Hu · Watertown, US
• Peter Jamison Rose · Littleton, US
• Kevin James GAGNON · Acton, US
• Yi-Qun Shi · East Brunswick Township, US
• Muna Shrestha · Belmont, US
• Ales Medek · Winchester, US
• Faith WITKOS · Attleboro, US

Key dates

• Filing date: Dec 17, 2019
• Grant date: Apr 4, 2023
• Expiry date: Dec 28, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).